Noteworthy, other carcinomas, neuropathy, and metabolic diseases (44–46) have a greater impact on the level of LCN2 in the blood, and the detection of stool may be more beneficial for diagnosis value of UCAC in subsequent use. Here, LCN2 is linked to carcinoma.